ID   SAE2_HUMAN              Reviewed;         640 AA.
AC   Q9UBT2; B3KWB9; O95605; Q59H87; Q6IBP6; Q9NTJ1; Q9UED2;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=SUMO-activating enzyme subunit 2;
DE            EC=6.3.2.-;
DE   AltName: Full=Anthracycline-associated resistance ARX;
DE   AltName: Full=Ubiquitin-like 1-activating enzyme E1B;
DE   AltName: Full=Ubiquitin-like modifier-activating enzyme 2;
GN   Name=UBA2; Synonyms=SAE2, UBLE1B; ORFNames=HRIHFB2115;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9920803; DOI=10.1006/bbrc.1998.9995;
RA   Okuma T., Honda R., Ichikawa G., Tsumagari N., Yasuda H.;
RT   "In vitro SUMO-1 modification requires two enzymatic steps, E1 and
RT   E2.";
RL   Biochem. Biophys. Res. Commun. 254:693-698(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RC   TISSUE=Placenta;
RX   PubMed=10217437; DOI=10.1016/S0014-5793(99)00367-1;
RA   Gong L., Li B., Millas S., Yeh E.T.H.;
RT   "Molecular cloning and characterization of human AOS1 and UBA2,
RT   components of the sentrin-activating enzyme complex.";
RL   FEBS Lett. 448:185-189(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10187858; DOI=10.1074/jbc.274.15.10618;
RA   Desterro J.M.P., Rodriguez M.S., Kemp G.D., Hay R.T.;
RT   "Identification of the enzyme required for activation of the small
RT   ubiquitin-like protein SUMO-1.";
RL   J. Biol. Chem. 274:10618-10624(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Slapak C., Mizunuma N., Terashima M., Yamauchi T., Kufe D.;
RL   Submitted (SEP-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 346-640 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 536-640 (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=9853615; DOI=10.1038/4315;
RA   Ueki N., Oda T., Kondo M., Yano K., Noguchi T., Muramatsu M.-A.;
RT   "Selection system for genes encoding nuclear-targeted proteins.";
RL   Nat. Biotechnol. 16:1338-1342(1998).
RN   [13]
RP   SUBCELLULAR LOCATION, DIMERIZATION, AND FUNCTION.
RX   PubMed=11481243;
RA   Azuma Y., Tan S.-H., Cavenagh M.M., Ainsztein A.M., Saitoh H.,
RA   Dasso M.;
RT   "Expression and regulation of the mammalian SUMO-1 E1 enzyme.";
RL   FASEB J. 15:1825-1827(2001).
RN   [14]
RP   FUNCTION.
RX   PubMed=11451954; DOI=10.1074/jbc.M104214200;
RA   Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M.P., Botting C.H.,
RA   Naismith J.H., Hay R.T.;
RT   "Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein
RT   substrates by SAE1/SAE2 and Ubc9.";
RL   J. Biol. Chem. 276:35368-35374(2001).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16620772; DOI=10.1016/j.abb.2006.03.002;
RA   Li T., Santockyte R., Shen R.-F., Tekle E., Wang G., Yang D.C.H.,
RA   Chock P.B.;
RT   "A general approach for investigating enzymatic pathways and
RT   substrates for ubiquitin-like modifiers.";
RL   Arch. Biochem. Biophys. 453:70-74(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-592, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   INTERACTION WITH UBE2I, FUNCTION, AND MUTAGENESIS OF ASP-484 AND
RP   GLY-485.
RX   PubMed=19443651; DOI=10.1074/jbc.M109.000257;
RA   Wang J., Lee B., Cai S., Fukui L., Hu W., Chen Y.;
RT   "Conformational transition associated with E1-E2 interaction in small
RT   ubiquitin-like modifications.";
RL   J. Biol. Chem. 284:20340-20348(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-271, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   SUMOYLATION AT LYS-190; LYS-236; LYS-257; LYS-271 AND LYS-275.
RX   PubMed=22403398; DOI=10.1074/jbc.M112.353789;
RA   Truong K., Lee T.D., Chen Y.;
RT   "Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain
RT   inhibits E1 Cys domain enzymatic activity.";
RL   J. Biol. Chem. 287:15154-15163(2012).
RN   [23]
RP   SUBCELLULAR LOCATION, AND SUMOYLATION AT LYS-611; LYS-613; LYS-617 AND
RP   LYS-623.
RX   PubMed=23095757; DOI=10.1074/jbc.M112.420877;
RA   Truong K., Lee T.D., Li B., Chen Y.;
RT   "Sumoylation of SAE2 C terminus regulates SAE nuclear localization.";
RL   J. Biol. Chem. 287:42611-42619(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-164 AND LYS-420, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-236, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEX WITH SAE1; SUMO1;
RP   ZINC IONS AND ATP, FUNCTION, SUBUNIT, AND ACTIVE SITE.
RX   PubMed=15660128; DOI=10.1038/sj.emboj.7600552;
RA   Lois L.M., Lima C.D.;
RT   "Structures of the SUMO E1 provide mechanistic insights into SUMO
RT   activation and E2 recruitment to E1.";
RL   EMBO J. 24:439-451(2005).
RN   [29]
RP   STRUCTURE BY NMR OF 166-382 IN COMPLEX WITH UBE2I, MUTAGENESIS OF
RP   ILE-235 AND ILE-238, FUNCTION, AND INTERACTION WITH UBE2I.
RX   PubMed=17643372; DOI=10.1016/j.molcel.2007.05.023;
RA   Wang J., Hu W., Cai S., Lee B., Song J., Chen Y.;
RT   "The intrinsic affinity between E2 and the Cys domain of E1 in
RT   ubiquitin-like modifications.";
RL   Mol. Cell 27:228-237(2007).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) IN COMPLEX WITH SAE1; SUMO1 AND
RP   REACTION INTERMEDIATE, FUNCTION, ACTIVE SITE, SUBUNIT, AND MUTAGENESIS
RP   OF ASN-56; LEU-57; ARG-59; LYS-72; ASP-117; CYS-173; THR-174 AND
RP   HIS-184.
RX   PubMed=20164921; DOI=10.1038/nature08765;
RA   Olsen S.K., Capili A.D., Lu X., Tan D.S., Lima C.D.;
RT   "Active site remodelling accompanies thioester bond formation in the
RT   SUMO E1.";
RL   Nature 463:906-912(2010).
CC   -!- FUNCTION: The heterodimer acts as an E1 ligase for SUMO1, SUMO2,
CC       SUMO3, and probably SUMO4. It mediates ATP-dependent activation of
CC       SUMO proteins followed by formation of a thioester bond between a
CC       SUMO protein and a conserved active site cysteine residue on
CC       UBA2/SAE2. {ECO:0000269|PubMed:11451954,
CC       ECO:0000269|PubMed:11481243, ECO:0000269|PubMed:15660128,
CC       ECO:0000269|PubMed:17643372, ECO:0000269|PubMed:19443651,
CC       ECO:0000269|PubMed:20164921}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Heterodimer of SAE1 and UBA2/SAE2. The heterodimer
CC       corresponds to the two domains that are encoded on a single
CC       polypeptide chain in ubiquitin-activating enzyme E1. Interacts
CC       with UBE2I. {ECO:0000269|PubMed:15660128,
CC       ECO:0000269|PubMed:17643372, ECO:0000269|PubMed:19443651,
CC       ECO:0000269|PubMed:20164921}.
CC   -!- INTERACTION:
CC       G2XKQ0:-; NbExp=5; IntAct=EBI-718569, EBI-10175576;
CC       Q9UBE0:SAE1; NbExp=8; IntAct=EBI-718569, EBI-743154;
CC       P63165:SUMO1; NbExp=5; IntAct=EBI-718569, EBI-80140;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles between
CC       the cytoplasm and the nucleus, sumoylation is required either for
CC       nuclear translocation or nuclear retention.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UBT2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UBT2-2; Sequence=VSP_056164;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Sumoylated with SUMO1 and SUMO2/3 and by UBC9. Sumoylation at
CC       Lys-236 inhibits enzymatic activity. Sumoylation at the C-terminal
CC       lysine cluster plays an essential role in nuclear trafficking.
CC       {ECO:0000269|PubMed:22403398, ECO:0000269|PubMed:23095757}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-activating E1 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF090384; AAD12784.1; -; mRNA.
DR   EMBL; AF079566; AAD23914.1; -; mRNA.
DR   EMBL; AF110957; AAD24434.1; -; mRNA.
DR   EMBL; U35832; AAC99992.1; -; mRNA.
DR   EMBL; AL136905; CAB66839.1; -; mRNA.
DR   EMBL; AK124730; BAG54081.1; -; mRNA.
DR   EMBL; BT009781; AAP88783.1; -; mRNA.
DR   EMBL; CR456756; CAG33037.1; -; mRNA.
DR   EMBL; AC008747; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC003153; AAH03153.1; -; mRNA.
DR   EMBL; AB208872; BAD92109.1; -; mRNA.
DR   EMBL; AB015337; BAA34795.1; -; mRNA.
DR   CCDS; CCDS12439.1; -. [Q9UBT2-1]
DR   PIR; T46936; T46936.
DR   RefSeq; NP_005490.1; NM_005499.2. [Q9UBT2-1]
DR   UniGene; Hs.631580; -.
DR   PDB; 1Y8Q; X-ray; 2.25 A; B/D=1-640.
DR   PDB; 1Y8R; X-ray; 2.75 A; B/E=1-640.
DR   PDB; 2PX9; NMR; -; A=166-382.
DR   PDB; 3KYC; X-ray; 2.45 A; B=1-640.
DR   PDB; 3KYD; X-ray; 2.61 A; B=1-549.
DR   PDB; 4W5V; X-ray; 2.50 A; B=445-561.
DR   PDB; 5FQ2; X-ray; 2.20 A; B=446-547.
DR   PDBsum; 1Y8Q; -.
DR   PDBsum; 1Y8R; -.
DR   PDBsum; 2PX9; -.
DR   PDBsum; 3KYC; -.
DR   PDBsum; 3KYD; -.
DR   PDBsum; 4W5V; -.
DR   PDBsum; 5FQ2; -.
DR   DisProt; DP00486; -.
DR   ProteinModelPortal; Q9UBT2; -.
DR   SMR; Q9UBT2; -.
DR   BioGrid; 115365; 80.
DR   DIP; DIP-35136N; -.
DR   IntAct; Q9UBT2; 15.
DR   MINT; MINT-1405216; -.
DR   STRING; 9606.ENSP00000246548; -.
DR   BindingDB; Q9UBT2; -.
DR   ChEMBL; CHEMBL2095174; -.
DR   iPTMnet; Q9UBT2; -.
DR   PhosphoSitePlus; Q9UBT2; -.
DR   SwissPalm; Q9UBT2; -.
DR   BioMuta; UBA2; -.
DR   DMDM; 42559898; -.
DR   EPD; Q9UBT2; -.
DR   PaxDb; Q9UBT2; -.
DR   PeptideAtlas; Q9UBT2; -.
DR   PRIDE; Q9UBT2; -.
DR   DNASU; 10054; -.
DR   Ensembl; ENST00000246548; ENSP00000246548; ENSG00000126261. [Q9UBT2-1]
DR   Ensembl; ENST00000439527; ENSP00000437484; ENSG00000126261. [Q9UBT2-2]
DR   GeneID; 10054; -.
DR   KEGG; hsa:10054; -.
DR   UCSC; uc002nvk.4; human. [Q9UBT2-1]
DR   CTD; 10054; -.
DR   DisGeNET; 10054; -.
DR   GeneCards; UBA2; -.
DR   HGNC; HGNC:30661; UBA2.
DR   HPA; HPA041436; -.
DR   MIM; 613295; gene.
DR   neXtProt; NX_Q9UBT2; -.
DR   OpenTargets; ENSG00000126261; -.
DR   PharmGKB; PA162407583; -.
DR   eggNOG; KOG2013; Eukaryota.
DR   eggNOG; COG0476; LUCA.
DR   GeneTree; ENSGT00550000074924; -.
DR   HOGENOM; HOG000216514; -.
DR   HOVERGEN; HBG060266; -.
DR   InParanoid; Q9UBT2; -.
DR   KO; K10685; -.
DR   OMA; VQWDTLL; -.
DR   OrthoDB; EOG091G07PV; -.
DR   PhylomeDB; Q9UBT2; -.
DR   TreeFam; TF300765; -.
DR   Reactome; R-HSA-3065676; SUMO is conjugated to E1 (UBA2:SAE1).
DR   Reactome; R-HSA-3065678; SUMO is transferred from E1 to E2 (UBE2I, UBC9).
DR   UniPathway; UPA00886; -.
DR   ChiTaRS; UBA2; human.
DR   EvolutionaryTrace; Q9UBT2; -.
DR   GeneWiki; UBA2; -.
DR   GenomeRNAi; 10054; -.
DR   PRO; PR:Q9UBT2; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000126261; -.
DR   CleanEx; HS_UBA2; -.
DR   ExpressionAtlas; Q9UBT2; baseline and differential.
DR   Genevisible; Q9UBT2; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0031510; C:SUMO activating enzyme complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IMP:CAFA.
DR   GO; GO:0008047; F:enzyme activator activity; TAS:ProtInc.
DR   GO; GO:0000287; F:magnesium ion binding; IMP:CAFA.
DR   GO; GO:0046982; F:protein heterodimerization activity; IMP:CAFA.
DR   GO; GO:0044388; F:small protein activating enzyme binding; IPI:CAFA.
DR   GO; GO:0019948; F:SUMO activating enzyme activity; IDA:UniProtKB.
DR   GO; GO:0032183; F:SUMO binding; IPI:CAFA.
DR   GO; GO:0008134; F:transcription factor binding; IEA:Ensembl.
DR   GO; GO:0044390; F:ubiquitin-like protein conjugating enzyme binding; IPI:CAFA.
DR   GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB.
DR   InterPro; IPR030661; SAE2/Uba2.
DR   InterPro; IPR000594; ThiF_NAD_FAD-bd.
DR   InterPro; IPR028077; UAE_UbL_dom.
DR   InterPro; IPR032426; UBA2_C.
DR   InterPro; IPR018074; UBQ-activ_enz_E1_CS.
DR   InterPro; IPR033127; UBQ-activ_enz_E1_Cys_AS.
DR   Pfam; PF00899; ThiF; 1.
DR   Pfam; PF14732; UAE_UbL; 1.
DR   Pfam; PF16195; UBA2_C; 1.
DR   PIRSF; PIRSF039133; SUMO_E1B; 1.
DR   SUPFAM; SSF69572; SSF69572; 2.
DR   PROSITE; PS00536; UBIQUITIN_ACTIVAT_1; 1.
DR   PROSITE; PS00865; UBIQUITIN_ACTIVAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Isopeptide bond; Ligase; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Ubl conjugation; Ubl conjugation pathway; Zinc.
FT   CHAIN         1    640       SUMO-activating enzyme subunit 2.
FT                                /FTId=PRO_0000194968.
FT   NP_BIND      24     29       ATP. {ECO:0000269|PubMed:15660128}.
FT   NP_BIND      56     59       ATP. {ECO:0000269|PubMed:15660128}.
FT   NP_BIND      95     96       ATP. {ECO:0000269|PubMed:15660128}.
FT   NP_BIND     117    122       ATP. {ECO:0000269|PubMed:15660128}.
FT   ACT_SITE    173    173       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10132,
FT                                ECO:0000269|PubMed:15660128,
FT                                ECO:0000269|PubMed:20164921}.
FT   METAL       158    158       Zinc.
FT   METAL       161    161       Zinc.
FT   METAL       441    441       Zinc.
FT   METAL       444    444       Zinc.
FT   BINDING      48     48       ATP. {ECO:0000269|PubMed:15660128}.
FT   BINDING      72     72       ATP. {ECO:0000269|PubMed:15660128}.
FT   MOD_RES     207    207       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     271    271       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     507    507       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     592    592       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     613    613       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9Z1F9}.
FT   CROSSLNK    164    164       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    190    190       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    236    236       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT   CROSSLNK    236    236       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    257    257       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    271    271       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   CROSSLNK    275    275       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    420    420       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    611    611       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    613    613       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   CROSSLNK    617    617       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    623    623       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1     96       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056164.
FT   VARIANT     307    307       L -> R (in dbSNP:rs1043062).
FT                                {ECO:0000269|PubMed:10217437,
FT                                ECO:0000269|PubMed:9920803}.
FT                                /FTId=VAR_017689.
FT   MUTAGEN      56     56       N->A: Abolishes ATP-dependent activation
FT                                of SUMO proteins.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN      57     57       L->A: Strongly reduces ATP-dependent
FT                                activation of SUMO proteins.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN      59     59       R->A: Strongly reduces ATP-dependent
FT                                activation of SUMO proteins.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN      72     72       K->A: Abolishes ATP-dependent activation
FT                                of SUMO proteins.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN     117    117       D->A: Abolishes ATP-dependent activation
FT                                of SUMO proteins.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN     173    173       C->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN     174    174       T->A: Slightly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN     184    184       H->Q: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:20164921}.
FT   MUTAGEN     235    235       I->A: Strongly reduced interaction with
FT                                UBE2I; when associated with A-238.
FT                                {ECO:0000269|PubMed:17643372}.
FT   MUTAGEN     238    238       I->A: Strongly reduced interaction with
FT                                UBE2I; when associated with A-235.
FT                                {ECO:0000269|PubMed:17643372}.
FT   MUTAGEN     484    484       Missing: Strongly reduced interaction
FT                                with UBE2I.
FT                                {ECO:0000269|PubMed:19443651}.
FT   MUTAGEN     485    485       G->GGGG: Strongly reduced interaction
FT                                with UBE2I.
FT                                {ECO:0000269|PubMed:19443651}.
FT   CONFLICT    229    229       S -> C (in Ref. 1; AAD12784 and 2;
FT                                AAD23914). {ECO:0000305}.
FT   CONFLICT    341    341       E -> G (in Ref. 5; CAB66839).
FT                                {ECO:0000305}.
FT   CONFLICT    456    456       V -> L (in Ref. 11; BAD92109).
FT                                {ECO:0000305}.
FT   HELIX         9     17       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND       19     23       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX        27     39       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND       43     48       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX        54     58       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX        65     67       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX        72     81       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND       88     94       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       103    106       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      110    114       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       119    132       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      136    142       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      145    151       {ECO:0000244|PDB:1Y8Q}.
FT   TURN        153    155       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      168    171       {ECO:0000244|PDB:3KYD}.
FT   TURN        172    176       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       182    197       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       202    204       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       213    215       {ECO:0000244|PDB:3KYC}.
FT   STRAND      225    227       {ECO:0000244|PDB:2PX9}.
FT   STRAND      234    236       {ECO:0000244|PDB:2PX9}.
FT   HELIX       241    246       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       251    259       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       261    266       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       270    272       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      274    276       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       284    289       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       308    310       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       315    335       {ECO:0000244|PDB:1Y8Q}.
FT   TURN        337    339       {ECO:0000244|PDB:1Y8R}.
FT   HELIX       349    365       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       373    381       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       388    406       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       410    412       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      414    418       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      426    433       {ECO:0000244|PDB:1Y8Q}.
FT   TURN        442    444       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      445    447       {ECO:0000244|PDB:1Y8Q}.
FT   STRAND      449    454       {ECO:0000244|PDB:5FQ2}.
FT   TURN        456    458       {ECO:0000244|PDB:5FQ2}.
FT   HELIX       461    466       {ECO:0000244|PDB:5FQ2}.
FT   HELIX       467    472       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      476    482       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      484    486       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      488    491       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      493    498       {ECO:0000244|PDB:1Y8Q}.
FT   HELIX       499    501       {ECO:0000244|PDB:5FQ2}.
FT   HELIX       506    509       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      516    525       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      527    534       {ECO:0000244|PDB:5FQ2}.
FT   STRAND      543    546       {ECO:0000244|PDB:5FQ2}.
FT   TURN        609    611       {ECO:0000244|PDB:3KYC}.
FT   TURN        614    619       {ECO:0000244|PDB:3KYC}.
FT   HELIX       620    626       {ECO:0000244|PDB:3KYC}.
FT   HELIX       627    629       {ECO:0000244|PDB:3KYC}.
FT   STRAND      636    638       {ECO:0000244|PDB:3KYC}.
SQ   SEQUENCE   640 AA;  71224 MW;  C12D15293BBF90EB CRC64;
     MALSRGLPRE LAEAVAGGRV LVVGAGGIGC ELLKNLVLTG FSHIDLIDLD TIDVSNLNRQ
     FLFQKKHVGR SKAQVAKESV LQFYPKANIV AYHDSIMNPD YNVEFFRQFI LVMNALDNRA
     ARNHVNRMCL AADVPLIESG TAGYLGQVTT IKKGVTECYE CHPKPTQRTF PGCTIRNTPS
     EPIHCIVWAK YLFNQLFGEE DADQEVSPDR ADPEAAWEPT EAEARARASN EDGDIKRIST
     KEWAKSTGYD PVKLFTKLFK DDIRYLLTMD KLWRKRKPPV PLDWAEVQSQ GEETNASDQQ
     NEPQLGLKDQ QVLDVKSYAR LFSKSIETLR VHLAEKGDGA ELIWDKDDPS AMDFVTSAAN
     LRMHIFSMNM KSRFDIKSMA GNIIPAIATT NAVIAGLIVL EGLKILSGKI DQCRTIFLNK
     QPNPRKKLLV PCALDPPNPN CYVCASKPEV TVRLNVHKVT VLTLQDKIVK EKFAMVAPDV
     QIEDGKGTIL ISSEEGETEA NNHKKLSEFG IRNGSRLQAD DFLQDYTLLI NILHSEDLGK
     DVEFEVVGDA PEKVGPKQAE DAAKSITNGS DDGAQPSTST AQEQDDVLIV DSDEEDSSNN
     ADVSEEERSR KRKLDEKENL SAKRSRIEQK EELDDVIALD
//
